Evidence map›Paper›PMID 38496764›Full record

ArticleFrontiers in oncology2024

Case report: Primary pulmonary low grade fibromyxoid sarcoma progressing to dedifferentiation: probably due to

Jiawen Zhang, Haisheng Fang, Xiaomei Zhu, Chenchen Yao, Qinhe Fan, Qixing Gong

Open access · goldAbstract readCase Reports
In one paragraph

Article in Frontiers in oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Jiawen Zhang *Department of Pathology, The First Affiliated Hospital with Nanjing Medical University, Nanjing, China.
Haisheng Fang *Department of Pathology, The First Affiliated Hospital with Nanjing Medical University, Nanjing, China.
Xiaomei ZhuDepartment of Radiology, The First Affiliated Hospital with Nanjing Medical University, Nanjing, China.
Chenchen YaoDepartment of Pathology, Women's and Children's Hospital Affiliated to Xiamen University (Xiamen Maternal and Child Health Care Hospital), Xiamen, China.
Qinhe FanDepartment of Pathology, The First Affiliated Hospital with Nanjing Medical University, Nanjing, China.
Qixing GongDepartment of Pathology, The First Affiliated Hospital with Nanjing Medical University, Nanjing, China.
Nanjing Medical University · CNXiamen University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Low Grade Fibromyxoid Sarcoma (LGFMS), a rare entity characterized by bland histologic features, typically affects deep soft tissues of the trunk and lower extremities. Rare cases have been reported arising from the viscera and few demonstrating morphology of high-grade dedifferentiation. Here we report a 39-year-old Chinese woman presenting with primary lung LGFMS, which metastasized to the pancreas five years after diagnosis and then relapsed ten years later as a mediastinum mass. Microscopically, the lung and pancreatic lumps shared similar classical features of LGFMS, composed of bland spindle-shaped cells with low mitotic activity. However, the mediastinal mass had dedifferentiated morphology of dense sheets of round and epithelioid cells with high degree of nuclear pleomorphism and brisk mitosis. Molecular studies showed both classical and dedifferentiated areas had FUS::CREB3L2 rearrangement. However, the mediastinal dedifferentiated area presented with extra H193Y mutation of the

Indexed as

dedifferentiatedLGFMSlungnext-generation sequencingTP53

Identifiers

PMID38496764
PMCPMC10940343
OpenAlexW4392352036

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.